Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 15/20 | 0.59 |
| ▸ | CSF1R | P07333 | 4/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934814 | 0.86 | BRAF (0.62) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL3940458 | 0.81 | BRAF (0.63) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL27720496 | 0.81 | BRAF (0.55) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL3943800 | 0.79 | BRAF (0.80) | BRAFCSF1RCYP11B2 | |
| SCHEMBL3934068 | 0.78 | BRAF (0.65) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL3932944 | 0.76 | BRAF (0.82) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL3937724 | 0.76 | CSF1R (0.83) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL3941714 | 0.76 | BRAF (0.83) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL3932898 | 0.76 | BRAF (0.59) | BRAFCSF1RKITKDRMAPK14 | |
| SCHEMBL3935960 | 0.75 | BRAF (0.68) | BRAFCSF1RKITKDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |